Actinic keratosis is a skin disease with the potential to progress to cutaneous squamous cell carcinoma, making its treatment essential. However, the last update of the Spanish adaptation of the European clinical guidelines dates back to 2014. This document includes the recommendations agreed upon by 75 primary care and dermatology experts on the optimal management of patients with actinic keratosis. In general, early and detailed diagnosis of actinic keratosis using dermoscopy and referral to dermatology is recommended, especially in high-risk patients. Regarding treatment, experts recommend the use of treatments adapted to the degree and extent of the injuries, highlighting the use of molecules such as 5-fluorouracil for isolated and field of cancerization injuries, as well as tirbanibulin for grade 1 and 2 isolated and field of cancerization injuries. These consensual recommendations seek to serve as a clinical guide on the routine management of patients with actinic keratosis.
